MeSH term
Frequency | Condition_Probility | Humans | 839 | 0.0 |
Aged | 103 | 0.0 |
Time Factors | 56 | 0.0 |
Adult | 235 | 0.0 |
Aged, 80 and over | 27 | 0.0 |
Female | 262 | 0.0 |
Immunohistochemistry | 17 | 0.0 |
Male | 231 | 0.0 |
Middle Aged | 188 | 0.0 |
Prognosis | 8 | 0.0 |
Research Support, Non-U.S. Gov't | 576 | 0.0 |
Animals | 145 | 0.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 2 | 1.0 |
DNA-Binding Proteins/metabolism | 9 | 0.0 |
Immunosuppressive Agents/*pharmacology | 15 | 7.0 |
JNK Mitogen-Activated Protein Kinases | 3 | 0.0 |
Jurkat Cells | 37 | 2.0 |
Lymphocyte Activation/drug effects | 33 | 5.0 |
Mice | 102 | 0.0 |
Mice, Inbred BALB C | 25 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
NF-kappa B/*antagonists & inhibitors | 2 | 4.0 |
Phosphorylation | 31 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
T-Lymphocytes/drug effects/immunology | 6 | 6.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
Antigens, CD/blood | 21 | 8.0 |
Antigens, CD11b/*blood | 2 | 66.0 |
Antigens, Differentiation, T-Lymphocyte/blood | 14 | 60.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 6 | 2.0 |
Neutrophils/*physiology | 3 | 2.0 |
Tetradecanoylphorbol Acetate/pharmacology | 37 | 2.0 |
Acquired Immunodeficiency Syndrome/*immunology | 3 | 1.0 |
Cell Division/drug effects | 24 | 0.0 |
Cytokines/blood | 7 | 3.0 |
HIV-1 | 3 | 1.0 |
Lymphocyte Activation | 129 | 4.0 |
Neutrophils/drug effects/immunology | 2 | 12.0 |
Reference Values | 17 | 0.0 |
Antigens, Bacterial/immunology | 3 | 2.0 |
CD4-Positive T-Lymphocytes/immunology | 21 | 2.0 |
Gene Expression Regulation/*immunology | 3 | 2.0 |
Immunoglobulin M/biosynthesis | 2 | 2.0 |
Immunologic Memory | 14 | 4.0 |
Immunophenotyping | 89 | 3.0 |
Interleukin-2/pharmacology | 27 | 4.0 |
Lymphocyte Cooperation | 2 | 2.0 |
Amino Acid Sequence | 34 | 0.0 |
Base Sequence | 35 | 0.0 |
Cloning, Molecular | 14 | 0.0 |
Gene Library | 3 | 0.0 |
Molecular Sequence Data | 50 | 0.0 |
Polymerase Chain Reaction | 8 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 23 | 0.0 |
Sequence Homology, Amino Acid | 15 | 0.0 |
Biological Markers | 38 | 2.0 |
Pregnancy | 19 | 0.0 |
*Cell Cycle Proteins | 6 | 0.0 |
*Cytotoxicity, Immunologic | 12 | 2.0 |
Enzyme Activation/immunology | 3 | 2.0 |
Enzyme Precursors/*metabolism | 2 | 1.0 |
Isoenzymes/metabolism | 3 | 0.0 |
Phospholipase C/metabolism | 8 | 2.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
Signal Transduction/*immunology | 12 | 3.0 |
Tumor Cells, Cultured | 51 | 0.0 |
src-Family Kinases/*physiology | 2 | 5.0 |
Adolescent | 58 | 0.0 |
Antigens, CD/analysis/*biosynthesis | 3 | 11.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*biosynthesis | 2 | 100.0 |
Down-Regulation | 13 | 0.0 |
Flow Cytometry | 178 | 2.0 |
Gene Expression Regulation | 17 | 0.0 |
Killer Cells, Natural/*immunology | 33 | 6.0 |
Phytohemagglutinins/immunology | 5 | 10.0 |
T-Lymphocytes | 2 | 0.0 |
Antigens, CD/*immunology | 26 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 19 | 8.0 |
Asthma/*immunology | 2 | 2.0 |
English Abstract | 19 | 0.0 |
Lipopolysaccharides/immunology | 2 | 1.0 |
Lymphocyte Activation/*immunology | 44 | 10.0 |
Monocytes/*immunology | 7 | 1.0 |
T-Lymphocytes/*immunology | 93 | 4.0 |
Comparative Study | 99 | 0.0 |
Eosinophils/drug effects/*metabolism | 2 | 33.0 |
Inflammation Mediators/metabolism | 4 | 5.0 |
Interleukin-5/pharmacology | 4 | 15.0 |
Predictive Value of Tests | 5 | 0.0 |
Antigens, CD/*metabolism | 40 | 6.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 35 | 30.0 |
Cell Division/physiology | 5 | 0.0 |
Cells, Cultured | 171 | 0.0 |
Child | 45 | 0.0 |
Child, Preschool | 31 | 0.0 |
Infant | 20 | 0.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Thymidine/metabolism | 9 | 2.0 |
Cell Differentiation | 15 | 0.0 |
Cell Movement/immunology | 4 | 4.0 |
Cell Survival | 4 | 0.0 |
Kinetics | 30 | 0.0 |
Mice, Inbred C57BL | 28 | 0.0 |
Mice, Knockout | 11 | 0.0 |
Mice, Transgenic | 10 | 0.0 |
Phenotype | 33 | 0.0 |
T-Lymphocytes/cytology/*immunology/physiology | 3 | 75.0 |
Thymus Gland/cytology/immunology | 2 | 4.0 |
CD4-Positive T-Lymphocytes/*physiology | 3 | 3.0 |
Cell Movement | 3 | 0.0 |
Chemokines, CC/physiology | 2 | 15.0 |
Cytokines/*biosynthesis | 8 | 2.0 |
Antigens, CD/*analysis | 27 | 3.0 |
Antigens, CD5/analysis | 3 | 6.0 |
B-Lymphocytes/*immunology | 11 | 1.0 |
Cell Membrane/*immunology | 2 | 11.0 |
Leukemia, B-Cell, Chronic/*immunology | 3 | 6.0 |
Research Support, U.S. Gov't, P.H.S. | 150 | 0.0 |
Antigens, CD/immunology | 30 | 6.0 |
Antigens, CD4/immunology | 5 | 2.0 |
Antigens, CD45/immunology | 6 | 9.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 21 | 11.0 |
Binding Sites | 15 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology | 30 | 3.0 |
Cell Membrane/immunology | 3 | 1.0 |
Hematopoietic Stem Cell Transplantation | 2 | 1.0 |
*Immunologic Memory | 5 | 3.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 2 | 1.0 |
Transplantation, Homologous/immunology | 3 | 7.0 |
Antigens, CD/analysis | 66 | 3.0 |
Antigens, CD30/*analysis | 2 | 10.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 54 | 16.0 |
Cell Cycle | 5 | 0.0 |
HIV Infections/*immunology | 10 | 2.0 |
HLA-DR Antigens/analysis | 21 | 3.0 |
*Lymphocyte Activation | 91 | 6.0 |
Receptors, Interleukin-2/analysis | 32 | 12.0 |
Antigens, CD/analysis/immunology | 2 | 4.0 |
Cell Count | 5 | 0.0 |
In Vitro | 56 | 0.0 |
Antigens, CD44/metabolism | 2 | 2.0 |
Asthma/blood | 2 | 18.0 |
Blood Cells/metabolism | 3 | 9.0 |
Bronchoalveolar Lavage Fluid/chemistry/cytology | 2 | 5.0 |
Intercellular Adhesion Molecule-1/analysis | 5 | 4.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
Up-Regulation | 33 | 1.0 |
Antigens, CD45 | 5 | 2.0 |
Bucladesine/pharmacology | 2 | 1.0 |
CD40 Ligand/genetics/*metabolism | 2 | 100.0 |
Cell Communication | 2 | 0.0 |
Coculture Techniques | 19 | 2.0 |
Phytohemagglutinins/pharmacology | 35 | 6.0 |
Signal Transduction/*physiology | 5 | 0.0 |
T-Lymphocytes/immunology/*metabolism | 6 | 6.0 |
Transfection | 17 | 0.0 |
Blotting, Western | 5 | 0.0 |
Cytokines/metabolism | 11 | 2.0 |
Electrophoresis | 2 | 0.0 |
Monocytes/drug effects/metabolism | 3 | 3.0 |
T-Lymphocytes/drug effects/metabolism | 2 | 5.0 |
Antibodies, Monoclonal/diagnostic use | 5 | 0.0 |
Biological Markers/blood | 17 | 1.0 |
HLA-DR Antigens/blood | 4 | 7.0 |
Receptors, Interleukin-2/blood | 8 | 10.0 |
Uveitis/*immunology | 3 | 21.0 |
Antigens, Differentiation, T-Lymphocyte/*biosynthesis/*blood | 2 | 100.0 |
*Bronchial Provocation Tests | 2 | 18.0 |
Eosinophil Granule Proteins | 7 | 3.0 |
*Ribonucleases | 7 | 3.0 |
Drugs, Chinese Herbal/*pharmacology | 2 | 4.0 |
Lymphocyte Activation/*drug effects | 42 | 12.0 |
Lymphocyte Culture Test, Mixed | 15 | 2.0 |
Rats | 9 | 0.0 |
Skin Transplantation/immunology | 2 | 8.0 |
T-Lymphocytes/immunology | 22 | 1.0 |
Biological Markers/analysis | 25 | 2.0 |
Cohort Studies | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 28 | 0.0 |
Probability | 5 | 0.0 |
Sensitivity and Specificity | 18 | 0.0 |
Severity of Illness Index | 13 | 1.0 |
Statistics, Nonparametric | 10 | 0.0 |
Antigens, CD/metabolism | 63 | 7.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 54 | 49.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Cell Line | 41 | 0.0 |
Interferon Type II/metabolism | 8 | 3.0 |
Lipopolysaccharides/pharmacology | 10 | 1.0 |
Monocytes/*physiology | 3 | 1.0 |
Receptors, Interleukin-2/metabolism | 24 | 13.0 |
Chronic Disease | 12 | 0.0 |
Cytokines/*metabolism | 9 | 3.0 |
Leukocytes/*immunology | 3 | 2.0 |
Membrane Glycoproteins/analysis | 6 | 2.0 |
Antigens, CD/biosynthesis | 58 | 18.0 |
Antigens, CD3/biosynthesis | 8 | 14.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis | 52 | 64.0 |
CD4-Positive T-Lymphocytes/metabolism | 7 | 5.0 |
Dose-Response Relationship, Immunologic | 9 | 1.0 |
Interferon Type II/biosynthesis | 25 | 5.0 |
Interleukin-2/biosynthesis | 21 | 4.0 |
Membrane Glycoproteins/biosynthesis | 7 | 4.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 3 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Receptors, Antigen, T-Cell/*metabolism | 7 | 4.0 |
*Signal Transduction | 7 | 0.0 |
Tyrosine/metabolism | 10 | 0.0 |
Antigens, CD3/analysis | 11 | 4.0 |
Antigens, CD4/analysis | 7 | 1.0 |
Antigens, Fungal/immunology | 3 | 14.0 |
Candida albicans/immunology | 2 | 4.0 |
Cells, Cultured/immunology | 2 | 15.0 |
Neopterin/*urine | 2 | 100.0 |
T-Lymphocyte Subsets/*immunology | 21 | 3.0 |
Mastocytosis/*metabolism | 2 | 50.0 |
*Adaptor Proteins, Signal Transducing | 6 | 0.0 |
Antigens, CD/genetics | 7 | 4.0 |
Antigens, Differentiation, T-Lymphocyte/genetics | 9 | 28.0 |
Biological Transport | 4 | 0.0 |
NF-kappa B/metabolism | 9 | 1.0 |
*Nuclear Proteins | 12 | 0.0 |
Promoter Regions (Genetics) | 9 | 0.0 |
Receptors, Antigen, T-Cell/*physiology | 6 | 3.0 |
Receptors, Interleukin-2/genetics | 3 | 7.0 |
Transcription Factor AP-1/metabolism | 4 | 1.0 |
Transcription Factors/metabolism | 12 | 0.0 |
Apoptosis/*physiology | 6 | 0.0 |
T-Lymphocytes/*physiology | 8 | 2.0 |
CD4-Positive T-Lymphocytes/*cytology/*immunology/metabolism | 2 | 25.0 |
Cell Communication/*immunology | 5 | 12.0 |
Cell Line, Transformed/immunology | 2 | 33.0 |
Clone Cells | 14 | 1.0 |
Signal Transduction/immunology | 12 | 3.0 |
T-Lymphocyte Subsets/*cytology/*immunology/metabolism | 2 | 16.0 |
Up-Regulation/immunology | 7 | 4.0 |
Antigens, CD45/metabolism | 4 | 4.0 |
Antigens, Surface/*metabolism | 4 | 6.0 |
Apoptosis | 14 | 0.0 |
Cytokines/pharmacology | 4 | 1.0 |
Inflammation/immunology | 5 | 4.0 |
Intercellular Adhesion Molecule-1/metabolism | 6 | 3.0 |
Macrophage-1 Antigen/metabolism | 4 | 5.0 |
*Staphylococcus aureus | 2 | 9.0 |
Antibodies, Monoclonal/*pharmacology | 5 | 2.0 |
Antigens, CD5/*immunology | 2 | 8.0 |
Apoptosis/*drug effects | 4 | 0.0 |
B-Lymphocytes/*cytology | 2 | 3.0 |
Neoplasm Staging | 3 | 0.0 |
Antigens, CD28/analysis | 3 | 8.0 |
*Apoptosis | 12 | 0.0 |
*Cell Communication | 2 | 2.0 |
Immune Tolerance | 4 | 1.0 |
Toxoplasma/*immunology | 3 | 13.0 |
Leukocytes, Mononuclear/*drug effects/physiology | 2 | 22.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 13 | 2.0 |
Antigens, CD45/*immunology | 4 | 12.0 |
Antigens, CD95/immunology | 4 | 7.0 |
Apoptosis/*immunology | 8 | 4.0 |
Enzyme Inhibitors/pharmacology | 11 | 0.0 |
Membrane Glycoproteins/immunology | 7 | 3.0 |
Case-Control Studies | 26 | 0.0 |
Lymphocyte Subsets/*immunology | 11 | 8.0 |
*Bacterial Toxins | 7 | 4.0 |
Cysteine Proteinase Inhibitors/pharmacology | 4 | 1.0 |
Disease Models, Animal | 5 | 0.0 |
Enterotoxins/immunology | 3 | 5.0 |
HLA-DR Antigens/metabolism | 4 | 2.0 |
Mice, SCID | 7 | 0.0 |
T-Lymphocytes/drug effects/*immunology | 10 | 6.0 |
Antigens, CD/biosynthesis/genetics | 6 | 17.0 |
Antigens, CD3/immunology | 23 | 8.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis/genetics | 6 | 60.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Common Variable Immunodeficiency/*immunology | 2 | 13.0 |
Herpesvirus 2, Saimiriine/*physiology | 2 | 22.0 |
Interferon Type II/biosynthesis/genetics | 3 | 8.0 |
Interleukin-2/biosynthesis/genetics | 5 | 12.0 |
Ionomycin/pharmacology | 13 | 5.0 |
Cell Survival/drug effects | 10 | 0.0 |
Tumor Necrosis Factor-alpha/secretion | 5 | 4.0 |
Antigens, Differentiation, T-Lymphocyte | 4 | 1.0 |
*Immunity, Cellular | 2 | 1.0 |
T-Lymphocyte Subsets/immunology | 12 | 3.0 |
Cytokines/biosynthesis | 24 | 4.0 |
HIV Infections/*drug therapy | 2 | 0.0 |
Receptors, CXCR4/biosynthesis | 2 | 6.0 |
T-Lymphocytes/*drug effects/immunology | 13 | 14.0 |
Cell Communication/drug effects/immunology | 3 | 60.0 |
Cell Differentiation/drug effects/immunology | 2 | 2.0 |
Cytotoxicity, Immunologic | 25 | 2.0 |
Interferon Type I, Recombinant/pharmacology | 2 | 6.0 |
Interleukin-12/biosynthesis | 4 | 4.0 |
Mycobacterium tuberculosis/immunology | 2 | 6.0 |
Antigens, CD8/metabolism | 4 | 7.0 |
CD8-Positive T-Lymphocytes/metabolism | 3 | 3.0 |
Infant, Newborn | 15 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/biosynthesis | 4 | 18.0 |
Reverse Transcriptase Polymerase Chain Reaction | 15 | 0.0 |
Antibodies, Monoclonal/pharmacology | 14 | 1.0 |
Antigens, CD/*biosynthesis/immunology | 3 | 12.0 |
Antigens, Differentiation, T-Lymphocyte/*biosynthesis/immunology | 4 | 80.0 |
Dose-Response Relationship, Drug | 22 | 0.0 |
*Immunophenotyping | 9 | 5.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Antigens, CD4/biosynthesis | 4 | 4.0 |
Receptors, Interleukin-2/biosynthesis | 16 | 15.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Antigens, CD/*blood | 13 | 7.0 |
Antigens, CD3/blood | 5 | 16.0 |
CD4-CD8 Ratio | 18 | 2.0 |
Immunity, Cellular | 13 | 1.0 |
Receptors, IgG/blood | 2 | 14.0 |
Cell Communication/physiology | 3 | 3.0 |
Cytotoxicity, Immunologic/drug effects/immunology | 2 | 20.0 |
Interferon-alpha/*pharmacology | 3 | 2.0 |
Killer Cells, Natural/drug effects/immunology | 5 | 16.0 |
Lymphocyte Activation/drug effects/*immunology | 7 | 16.0 |
Lymphocytes/drug effects/*immunology | 5 | 12.0 |
Apoptosis/drug effects | 8 | 1.0 |
Killer Cells, Natural/*metabolism | 4 | 6.0 |
Tumor Necrosis Factor-alpha/metabolism | 7 | 0.0 |
Cell Differentiation/genetics/immunology | 3 | 3.0 |
Lymphocyte Activation/genetics | 4 | 4.0 |
T-Lymphocytes, Helper-Inducer/*cytology/immunology | 2 | 66.0 |
Antigen Presentation | 5 | 1.0 |
Immunoassay/*methods | 2 | 2.0 |
Antigens, CD3/metabolism | 10 | 6.0 |
Immunity, Cellular/*drug effects | 2 | 4.0 |
Enhancer Elements (Genetics) | 3 | 0.0 |
Feasibility Studies | 2 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Lymphocyte Activation/genetics/*physiology | 2 | 100.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Receptors, Antigen, T-Cell/*immunology | 9 | 5.0 |
Signal Transduction | 33 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Kidney Transplantation/*immunology | 2 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis | 4 | 8.0 |
Transplantation, Homologous | 11 | 1.0 |
Annexin A5/metabolism | 4 | 4.0 |
Antigens, CD95/metabolism | 3 | 2.0 |
Leukocyte Count | 19 | 1.0 |
Exocytosis/*physiology | 2 | 6.0 |
Macrophage-1 Antigen/immunology | 2 | 15.0 |
Neutrophils/*cytology/immunology | 2 | 66.0 |
Cell Division | 35 | 0.0 |
Intracellular Fluid/metabolism | 3 | 2.0 |
Leukocytes, Mononuclear/cytology/immunology | 3 | 6.0 |
Lymphocyte Activation/immunology | 36 | 6.0 |
Membrane Glycoproteins/metabolism | 8 | 1.0 |
Monocytes/metabolism | 6 | 1.0 |
Serine Endopeptidases/*immunology | 2 | 15.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
RNA, Messenger/biosynthesis | 11 | 0.0 |
Antibodies, Monoclonal/immunology | 11 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 21 | 10.0 |
CD4-Positive T-Lymphocytes/*cytology/immunology | 3 | 13.0 |
Microspheres | 2 | 1.0 |
Reproducibility of Results | 5 | 0.0 |
Adjuvants, Immunologic/*pharmacology | 5 | 3.0 |
Interferon-alpha/*physiology | 2 | 15.0 |
Oligodeoxyribonucleotides/*pharmacology | 2 | 6.0 |
Aging/*immunology | 11 | 9.0 |
CD4 Lymphocyte Count | 8 | 0.0 |
CD4-Positive T-Lymphocytes/drug effects/*immunology | 3 | 7.0 |
Lymphocyte Count | 17 | 2.0 |
Receptors, Antigen, T-Cell/immunology | 6 | 3.0 |
Cell Division/drug effects/immunology | 3 | 4.0 |
Genotype | 2 | 0.0 |
Mitogens/pharmacology | 19 | 7.0 |
Antibodies, Bacterial/blood | 2 | 2.0 |
HIV Infections/*immunology/virology | 2 | 3.0 |
*HIV-1 | 6 | 0.0 |
Immunoglobulin G/blood | 4 | 1.0 |
Progesterone/*pharmacology | 2 | 2.0 |
Signal Transduction/*drug effects | 4 | 1.0 |
Umbilical Veins/cytology | 2 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis | 4 | 13.0 |
Cell Cycle/immunology | 2 | 6.0 |
Cell Differentiation/immunology | 4 | 1.0 |
Ligands | 16 | 0.0 |
Lymphocyte Activation/genetics/*immunology | 2 | 11.0 |
Signal Transduction/genetics/*immunology | 5 | 5.0 |
Antigens, CD11/analysis | 3 | 10.0 |
Antigens, CD18/analysis | 2 | 9.0 |
Antigens, CD44/analysis | 3 | 4.0 |
Endothelium, Vascular/*immunology | 3 | 3.0 |
Heterozygote | 2 | 0.0 |
Intercellular Adhesion Molecule-1/blood | 3 | 3.0 |
Interleukin-1/blood | 2 | 1.0 |
Lymphocytes/*immunology | 9 | 2.0 |
Receptors, Complement 3b/analysis | 2 | 13.0 |
Tumor Necrosis Factor-alpha/analysis | 7 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 6 | 3.0 |
Photomicrography | 2 | 14.0 |
Staining and Labeling | 2 | 0.0 |
Tetradecanoylphorbol Acetate | 3 | 4.0 |
Down-Regulation/drug effects | 3 | 1.0 |
Fluorescent Antibody Technique | 17 | 0.0 |
*T-Lymphocytes | 2 | 4.0 |
Zambia | 2 | 14.0 |
*Receptors, Tumor Necrosis Factor | 3 | 7.0 |
Treatment Outcome | 8 | 0.0 |
Graft vs Host Disease/*immunology | 2 | 7.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
Isoantigens/*immunology | 2 | 2.0 |
L-Selectin/biosynthesis | 2 | 10.0 |
Receptors, Interleukin-2/biosynthesis/genetics | 2 | 20.0 |
B-Lymphocytes/cytology/immunology | 2 | 6.0 |
Calcium/metabolism | 23 | 1.0 |
DNA, Complementary | 3 | 0.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
Receptors, Antigen, B-Cell/*immunology | 2 | 5.0 |
Trans-Activation (Genetics) | 5 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
*src Homology Domains | 2 | 1.0 |
Antigens, Surface/*biosynthesis | 3 | 12.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Cell Culture Techniques | 10 | 2.0 |
Cross-Sectional Studies | 3 | 0.0 |
Monocytes/*drug effects | 2 | 3.0 |
Multiple Sclerosis/*immunology | 2 | 1.0 |
Antigens, CD4/*immunology | 2 | 0.0 |
DNA Primers | 6 | 0.0 |
HIV-1/*physiology | 2 | 0.0 |
Immunomagnetic Separation | 2 | 1.0 |
T-Lymphocyte Subsets | 8 | 6.0 |
Viral Load | 2 | 0.0 |
Antigens, CD28/metabolism | 5 | 5.0 |
Interleukin-4/biosynthesis | 5 | 3.0 |
Killer Cells, Natural/immunology | 15 | 3.0 |
B-Lymphocytes/immunology | 6 | 0.0 |
Hamsters | 2 | 0.0 |
Protein Binding | 10 | 0.0 |
Solubility | 13 | 0.0 |
Antigens, CD45/blood | 2 | 8.0 |
Cytotoxicity, Immunologic/drug effects | 7 | 5.0 |
Fetal Blood/*immunology | 4 | 5.0 |
Gene Expression Regulation/immunology | 3 | 1.0 |
Interferon Type II/biosynthesis/blood | 2 | 11.0 |
Interleukin-12/pharmacology | 3 | 6.0 |
RNA, Messenger/genetics | 7 | 0.0 |
Recombinant Proteins/pharmacology | 12 | 0.0 |
CD8-Positive T-Lymphocytes/*immunology | 20 | 6.0 |
Flow Cytometry/methods | 6 | 2.0 |
HLA-DR Antigens/*metabolism | 5 | 8.0 |
Health Status | 2 | 2.0 |
Leukocytes, Mononuclear/immunology | 5 | 1.0 |
Receptors, CCR5/*metabolism | 2 | 1.0 |
Receptors, CXCR4/*metabolism | 3 | 1.0 |
Receptors, Interleukin-2/*metabolism | 7 | 9.0 |
Antibodies, Monoclonal/*therapeutic use | 2 | 0.0 |
Antigens, CD56/analysis | 4 | 6.0 |
Interleukin-2/*pharmacology | 8 | 3.0 |
Killer Cells, Natural/drug effects/*immunology | 6 | 17.0 |
Receptors, IgG/physiology | 2 | 5.0 |
Cross-Linking Reagents/pharmacology | 3 | 2.0 |
Enzyme Activation | 10 | 0.0 |
MAP Kinase Kinase 1 | 2 | 1.0 |
Models, Biological | 7 | 0.0 |
Precipitin Tests | 8 | 0.0 |
Protein Kinase C/metabolism | 3 | 0.0 |
Hydrolysis | 2 | 0.0 |
Phosphatidylinositols/metabolism | 4 | 3.0 |
*Signal Transduction/drug effects | 2 | 2.0 |
T-Lymphocytes/*immunology/metabolism | 14 | 8.0 |
Antigen-Presenting Cells/immunology | 6 | 2.0 |
Antigens, Viral/*immunology | 4 | 4.0 |
Superantigens/immunology | 6 | 12.0 |
Antibodies/immunology | 3 | 0.0 |
Immunoglobulin Variable Region/immunology | 2 | 6.0 |
Receptors, Antigen, T-Cell, alpha-beta/immunology | 5 | 8.0 |
Virus Replication | 3 | 0.0 |
Bronchoalveolar Lavage Fluid/cytology/immunology | 2 | 5.0 |
Lymphocyte Subsets/drug effects/immunology | 2 | 10.0 |
Neutrophils/drug effects/*immunology | 2 | 6.0 |
Particle Size | 2 | 0.0 |
Concanavalin A/pharmacology | 4 | 1.0 |
Culture Media | 2 | 0.0 |
Lymphocyte Activation/*physiology | 2 | 2.0 |
*Weightlessness Simulation | 2 | 22.0 |
Survival Analysis | 2 | 0.0 |
Antigen Presentation/immunology | 4 | 5.0 |
Antigens, CD/biosynthesis/immunology | 4 | 14.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis/immunology | 3 | 42.0 |
Antigens, Neoplasm/immunology | 2 | 1.0 |
Cancer Vaccines/*immunology | 2 | 3.0 |
Dendritic Cells/*immunology | 7 | 2.0 |
HLA-A2 Antigen/immunology | 2 | 5.0 |
Interferon Type II/secretion | 6 | 5.0 |
T-Lymphocytes, Cytotoxic/*immunology | 5 | 0.0 |
Antigens, Surface/*blood | 2 | 13.0 |
Monocytes/*metabolism | 3 | 0.0 |
*Antigens, Ly | 2 | 20.0 |
Carrier Proteins/chemistry/genetics/metabolism | 2 | 11.0 |
Macromolecular Substances | 2 | 0.0 |
Models, Molecular | 7 | 0.0 |
Molecular Structure | 2 | 0.0 |
ADP-ribosyl Cyclase | 2 | 0.0 |
Antigens, Differentiation/*metabolism | 2 | 1.0 |
Lymphocytes/immunology/*metabolism | 2 | 8.0 |
*Antigens, CD | 10 | 1.0 |
Sialoglycoproteins/*metabolism | 3 | 10.0 |
Antigens, CD/drug effects/metabolism | 2 | 18.0 |
Interleukin-2/metabolism | 11 | 7.0 |
RNA, Messenger/metabolism | 10 | 0.0 |
Cytokines/secretion | 4 | 5.0 |
Cytotoxicity Tests, Immunologic | 8 | 1.0 |
Herpesvirus 4, Human/*immunology | 3 | 4.0 |
Cell Adhesion Molecules/metabolism | 7 | 2.0 |
Hepacivirus/*immunology | 2 | 6.0 |
Hepatitis B Core Antigens/immunology | 2 | 22.0 |
Antigens, CD56/*analysis | 3 | 9.0 |
Incidence | 3 | 0.0 |
Killer Cells, Natural/*immunology/pathology | 2 | 16.0 |
Receptors, IgG/*analysis | 2 | 6.0 |
Antigens, Surface/genetics/metabolism | 2 | 15.0 |
Cycloheximide/pharmacology | 6 | 0.0 |
*Lectins, C-Type | 13 | 7.0 |
Protein Synthesis Inhibitors/pharmacology | 6 | 1.0 |
Receptors, Cell Surface/genetics/metabolism | 2 | 3.0 |
Antigens, CD45/analysis | 11 | 4.0 |
Bronchoalveolar Lavage Fluid | 2 | 4.0 |
Up-Regulation/genetics/immunology | 2 | 3.0 |
Cell Death/drug effects | 2 | 1.0 |
Cyclosporine/*pharmacology | 4 | 3.0 |
T-Lymphocytes/*drug effects/*immunology | 6 | 40.0 |
Immunotherapy/*methods | 2 | 1.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 2 | 2.0 |
Diagnosis, Differential | 2 | 0.0 |
*Flow Cytometry | 4 | 2.0 |
Calcimycin/pharmacology | 5 | 2.0 |
Calcineurin/antagonists & inhibitors | 2 | 16.0 |
Drug Synergism | 6 | 0.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Ionophores/pharmacology | 8 | 5.0 |
Acute Disease | 13 | 0.0 |
Lymphocytes/immunology | 8 | 2.0 |
Pancreatitis/*immunology | 2 | 18.0 |
Eosinophils/*immunology | 7 | 11.0 |
Integrin alpha4beta1 | 3 | 3.0 |
Integrins/*metabolism | 2 | 1.0 |
Receptors, Lymphocyte Homing/*metabolism | 2 | 6.0 |
Exercise/*physiology | 3 | 0.0 |
Antibodies, Monoclonal/immunology/pharmacology | 3 | 3.0 |
Dendritic Cells/immunology | 3 | 2.0 |
Enterotoxins/*immunology/pharmacology | 2 | 25.0 |
Monocytes/immunology | 4 | 1.0 |
Lung/*immunology | 2 | 4.0 |
Sarcoidosis, Pulmonary/*immunology | 2 | 11.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Receptors, Antigen, T-Cell/metabolism | 5 | 2.0 |
T-Lymphocytes/immunology/metabolism | 7 | 5.0 |
Antigens, CD4/blood | 2 | 3.0 |
Lymphocytes/immunology/metabolism | 2 | 6.0 |
Major Histocompatibility Complex | 5 | 2.0 |
Blood Sedimentation | 2 | 1.0 |
Cytokines/*blood | 4 | 1.0 |
Neutrophils/*metabolism | 2 | 1.0 |
Antigens, CD3/*immunology | 9 | 8.0 |
*Clonal Anergy | 2 | 6.0 |
Antigens, CD | 4 | 3.0 |
Peptide Fragments/*immunology | 2 | 1.0 |
Tissue Distribution | 3 | 0.0 |
Antigens, CD8/analysis | 6 | 2.0 |
Antibodies, Monoclonal | 14 | 0.0 |
Karyotyping | 3 | 0.0 |
Macrophages/immunology | 5 | 1.0 |
Interleukins/metabolism | 2 | 6.0 |
Neck | 2 | 3.0 |
Eosinophils/drug effects/*immunology | 2 | 22.0 |
Hematopoietic Stem Cells/cytology | 2 | 2.0 |
Interferon Type II/*pharmacology | 3 | 0.0 |
Interleukin-5/*pharmacology | 2 | 6.0 |
Biopsy, Needle | 2 | 0.0 |
Antigens, CD/biosynthesis/metabolism | 3 | 27.0 |
CD4-Positive T-Lymphocytes/*metabolism | 3 | 3.0 |
*Cancer Vaccines | 3 | 11.0 |
Immunoglobulins/metabolism | 2 | 1.0 |
Integrin alpha4 | 2 | 5.0 |
Immunoblotting | 2 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Immunotherapy/methods | 3 | 3.0 |
Receptors, Fc/metabolism | 2 | 4.0 |
Chromosome Banding | 2 | 0.0 |
Protein Kinase C/*metabolism | 5 | 1.0 |
Cytomegalovirus/*immunology | 2 | 3.0 |
Epitopes, T-Lymphocyte/*immunology | 3 | 5.0 |
Major Histocompatibility Complex/physiology | 2 | 12.0 |
Antigens, Bacterial/*immunology | 2 | 1.0 |
Fluorescent Antibody Technique, Direct | 4 | 3.0 |
Superantigens/*immunology | 2 | 2.0 |
Antigens, CD/genetics/*physiology | 2 | 5.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
Antigens, CD34/*blood | 2 | 2.0 |
CD8-Positive T-Lymphocytes/immunology | 10 | 2.0 |
Interleukins/blood | 3 | 7.0 |
Regression Analysis | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Interferon Type II/blood | 3 | 2.0 |
Dimerization | 5 | 0.0 |
Histocompatibility Antigens Class I/immunology | 2 | 1.0 |
Lectins, C-Type | 2 | 25.0 |
Protein Structure, Secondary | 2 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Antibodies/pharmacology | 4 | 1.0 |
Antigens, CD/pharmacology | 2 | 22.0 |
Antigens, CD3/immunology/physiology | 2 | 28.0 |
Antigens, Differentiation, T-Lymphocyte/pharmacology | 2 | 100.0 |
Signal Transduction/drug effects | 6 | 0.0 |
Up-Regulation/drug effects | 6 | 1.0 |
Lymphocytes/*immunology/metabolism | 3 | 13.0 |
Antigens, CD/*physiology | 12 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/*physiology | 9 | 6.0 |
Eosinophils/*physiology | 2 | 4.0 |
B-Lymphocytes/drug effects/immunology | 3 | 10.0 |
Epitopes, T-Lymphocyte/immunology | 4 | 4.0 |
Immunotherapy, Adoptive/*methods | 3 | 7.0 |
T-Lymphocyte Subsets/drug effects/*immunology | 2 | 7.0 |
Transduction, Genetic | 2 | 0.0 |
T-Lymphocytes/metabolism/*physiology | 2 | 15.0 |
Binding Sites/immunology | 2 | 3.0 |
Glycoproteins/metabolism | 2 | 1.0 |
Immunosuppressive Agents/metabolism/*pharmacology | 2 | 66.0 |
Protein Kinase C/physiology | 7 | 4.0 |
Antigens, CD/*biosynthesis | 28 | 14.0 |
Stimulation, Chemical | 5 | 1.0 |
Antigens, Viral/immunology | 3 | 2.0 |
*Antiretroviral Therapy, Highly Active | 2 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism | 2 | 3.0 |
Cytomegalovirus/immunology | 3 | 4.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
HIV-1/*immunology | 4 | 0.0 |
HIV Long Terminal Repeat | 2 | 1.0 |
Cattle | 3 | 0.0 |
CpG Islands/*immunology | 3 | 18.0 |
Escherichia coli/genetics | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology | 3 | 10.0 |
Oligodeoxyribonucleotides/*immunology | 2 | 22.0 |
Thymus Gland | 2 | 10.0 |
Cell Separation/*methods | 2 | 1.0 |
Flow Cytometry/*methods | 14 | 6.0 |
Interferon Type II/analysis | 4 | 4.0 |
Interleukin-2/analysis | 2 | 4.0 |
Binding Sites, Antibody | 5 | 1.0 |
Cross Reactions | 3 | 0.0 |
Epitopes/analysis | 2 | 0.0 |
T-Lymphocytes, Helper-Inducer | 2 | 6.0 |
Tuberculin/immunology | 2 | 3.0 |
Lymph Nodes/immunology | 2 | 2.0 |
Mice, Mutant Strains | 3 | 0.0 |
Receptors, Interleukin-2/*biosynthesis | 5 | 12.0 |
Chemotaxis, Leukocyte | 3 | 1.0 |
Germinal Center/immunology | 2 | 16.0 |
Tonsil/cytology | 2 | 2.0 |
Endometrium/cytology/*immunology | 3 | 50.0 |
Menstrual Cycle/immunology | 2 | 40.0 |
Antigens, CD/*chemistry | 2 | 7.0 |
Antigens, Differentiation, T-Lymphocyte/*chemistry | 2 | 40.0 |
Crystallography, X-Ray | 3 | 0.0 |
Lectins/*chemistry | 2 | 25.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Receptors, Cell Surface/*physiology | 3 | 1.0 |
Macaca nemestrina | 2 | 6.0 |
Interleukin-2/secretion | 8 | 11.0 |
Models, Immunological | 5 | 2.0 |
Protein-Tyrosine Kinase/*physiology | 2 | 1.0 |
Phosphotyrosine/metabolism | 3 | 0.0 |
Antigens/immunology | 2 | 1.0 |
Interleukin-2/immunology | 8 | 7.0 |
Cell Division/immunology | 12 | 4.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 2 | 1.0 |
T-Lymphocytes/cytology/drug effects/*immunology | 3 | 11.0 |
CD8-Positive T-Lymphocytes/*immunology/virology | 2 | 11.0 |
Immune Tolerance/immunology | 4 | 8.0 |
Dogs | 2 | 0.0 |
Integrin alpha1beta1 | 2 | 14.0 |
Interleukin-12/*pharmacology | 2 | 4.0 |
Interleukin-15/*pharmacology | 4 | 25.0 |
Killer Cells, Natural/drug effects/*metabolism | 3 | 60.0 |
T-Lymphocytes/drug effects/*metabolism | 8 | 16.0 |
*Biological Markers | 2 | 1.0 |
Killer Cells, Natural/metabolism | 5 | 9.0 |
T-Lymphocytes/metabolism | 8 | 2.0 |
Drug Interactions | 2 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Antigens, CD/genetics/immunology/*metabolism | 2 | 12.0 |
Antigens, Differentiation, T-Lymphocyte/genetics/immunology/*metabolism | 2 | 28.0 |
Tyrosine/antagonists & inhibitors/metabolism | 2 | 22.0 |
Antigens, CD27/*metabolism | 2 | 14.0 |
*Immunization | 2 | 4.0 |
Leukocytes, Mononuclear/chemistry/metabolism | 2 | 25.0 |
COS Cells | 2 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
Membrane Proteins/genetics/*metabolism | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Antigens, Surface/analysis | 5 | 1.0 |
Interleukin-1/pharmacology | 3 | 0.0 |
Interleukin-5/immunology | 2 | 12.0 |
RNA, Messenger/analysis | 9 | 0.0 |
Respiratory Burst/immunology | 2 | 20.0 |
Tumor Necrosis Factor-alpha/pharmacology | 5 | 0.0 |
Infant, Premature | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*blood | 8 | 53.0 |
Hypersensitivity, Delayed/immunology | 2 | 3.0 |
HLA-DR Antigens/*analysis | 3 | 1.0 |
Macaca mulatta | 3 | 0.0 |
Prospective Studies | 8 | 0.0 |
Cytokines/analysis | 2 | 2.0 |
Carcinoembryonic Antigen/*immunology | 2 | 11.0 |
Cytokines/biosynthesis/immunology | 4 | 22.0 |
CD8-Positive T-Lymphocytes/drug effects/immunology | 4 | 17.0 |
Cell Differentiation/drug effects | 4 | 0.0 |
Cytokines/physiology | 3 | 1.0 |
Lymphocyte Activation/drug effects/immunology | 7 | 11.0 |
Poly I-C/pharmacology | 2 | 8.0 |
Species Specificity | 3 | 0.0 |
HLA-DR Antigens/biosynthesis | 6 | 6.0 |
Graft vs Host Disease/prevention & control | 2 | 3.0 |
Immunotherapy, Adoptive | 2 | 2.0 |
Lymphocyte Depletion/*methods | 3 | 13.0 |
Fetus/immunology | 2 | 5.0 |
*Blood Donors | 2 | 1.0 |
Antigens, CD56/metabolism | 3 | 11.0 |
Cell Adhesion/drug effects | 5 | 1.0 |
Infant, Newborn/*immunology | 2 | 8.0 |
Pokeweed Mitogens/pharmacology | 3 | 3.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Cyclosporine/pharmacology | 10 | 4.0 |
DNA/*metabolism | 2 | 0.0 |
NF-kappa B/genetics/*metabolism | 3 | 4.0 |
Protein Kinase C/antagonists & inhibitors/metabolism | 2 | 2.0 |
Proto-Oncogene Proteins c-fos/metabolism | 2 | 1.0 |
Proto-Oncogene Proteins c-jun/metabolism | 3 | 2.0 |
Staurosporine/pharmacology | 2 | 1.0 |
HLA-DR Antigens/immunology | 3 | 1.0 |
Interferon Type II/pharmacology | 6 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*biosynthesis | 25 | 67.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
*Up-Regulation | 3 | 1.0 |
ras Proteins/*metabolism | 2 | 1.0 |
Ascitic Fluid/cytology | 2 | 10.0 |
*Allergens | 2 | 12.0 |
*Chemokines, CC | 2 | 2.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/analysis | 2 | 8.0 |
Interleukin-4/analysis | 2 | 5.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
Skin/*immunology | 2 | 1.0 |
Diphosphonates/*pharmacology | 2 | 20.0 |
Antigens, CD80/immunology | 2 | 3.0 |
Adoptive Transfer | 3 | 3.0 |
*Antigens, Differentiation, T-Lymphocyte | 2 | 6.0 |
Cell Separation/methods | 3 | 1.0 |
Graft vs Host Disease/*prevention & control | 2 | 7.0 |
Apoptosis/immunology | 4 | 4.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Lymphocyte Activation/*drug effects/immunology | 3 | 13.0 |
Proteins/metabolism | 2 | 0.0 |
Leukotriene C4/biosynthesis | 3 | 37.0 |
Peroxidases/metabolism | 2 | 8.0 |
Phospholipases A/*physiology | 3 | 42.0 |
Recombinant Proteins | 4 | 0.0 |
Biopsy | 4 | 0.0 |
Evaluation Studies | 4 | 0.0 |
Follow-Up Studies | 9 | 0.0 |
Lymphocyte Activation/physiology | 6 | 8.0 |
Protein-Serine-Threonine Kinases/*physiology | 2 | 1.0 |
Radiation Tolerance | 2 | 2.0 |
Cell Aggregation/drug effects | 2 | 4.0 |
Sialoglycoproteins/*biosynthesis | 2 | 10.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 2 | 2.0 |
Pertussis Toxin | 2 | 1.0 |
Receptors, Antigen, T-Cell/physiology | 5 | 3.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
CD8-Positive T-Lymphocytes/cytology/drug effects/*immunology | 2 | 25.0 |
Endothelium, Vascular/cytology/*immunology | 2 | 6.0 |
*Lymphocyte Activation/drug effects | 8 | 7.0 |
T-Lymphocyte Subsets/cytology/*immunology | 3 | 12.0 |
CD40 Ligand | 13 | 7.0 |
Muromonab-CD3/pharmacology | 2 | 2.0 |
T-Lymphocytes/*drug effects/metabolism | 5 | 14.0 |
Cell Death | 2 | 0.0 |
Interleukin-12/immunology | 2 | 9.0 |
Lymphocyte Subsets/immunology | 4 | 2.0 |
Porphyromonas gingivalis/*immunology | 2 | 9.0 |
Receptors, Antigen, T-Cell, gamma-delta/immunology | 2 | 9.0 |
Antigens, Protozoan/immunology | 2 | 6.0 |
Toxoplasmosis/*immunology | 2 | 20.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
*Ultraviolet Rays | 2 | 0.0 |
Antigens, CD3/*metabolism | 4 | 8.0 |
Apoptosis/drug effects/*immunology | 3 | 7.0 |
Concanavalin A/*pharmacology | 2 | 7.0 |
Immunosuppressive Agents/pharmacology | 6 | 3.0 |
K562 Cells | 5 | 1.0 |
T-Lymphocyte Subsets/*immunology/*metabolism | 3 | 11.0 |
Eosinophils/*immunology/metabolism | 2 | 33.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 3 | 0.0 |
Neutrophils/immunology | 2 | 1.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*metabolism | 3 | 7.0 |
Phosphoproteins/metabolism | 5 | 0.0 |
Receptors, Interleukin-2/immunology | 4 | 6.0 |
Th2 Cells/*immunology | 2 | 1.0 |
Cell Proliferation/drug effects | 2 | 2.0 |
Gene Expression Regulation/drug effects/immunology | 3 | 8.0 |
Interleukin-10/immunology | 2 | 7.0 |
Receptors, Interleukin-2/*immunology | 2 | 4.0 |
Blood Donors | 2 | 0.0 |
Cell Adhesion Molecules/immunology | 3 | 4.0 |
Cytokines/immunology | 5 | 3.0 |
Actins/metabolism | 2 | 0.0 |
Cell Membrane/metabolism | 6 | 0.0 |
Interleukin-2/genetics | 6 | 6.0 |
Rabbits | 2 | 0.0 |
Arthritis, Rheumatoid/*immunology | 9 | 4.0 |
CD4-Positive T-Lymphocytes/drug effects/immunology | 4 | 9.0 |
Cytokines/*immunology | 3 | 3.0 |
Antigens, CD/analysis/physiology | 2 | 16.0 |
CD4-Positive T-Lymphocytes/cytology/drug effects/*immunology | 2 | 15.0 |
Cytokines/*biosynthesis/genetics | 2 | 2.0 |
Concanavalin A/immunology | 2 | 11.0 |
Gene Expression/drug effects | 6 | 0.0 |
Molecular Weight | 8 | 0.0 |
Monocytes/physiology | 3 | 2.0 |
*Receptors, Cell Surface | 3 | 0.0 |
Membrane Glycoproteins/*immunology | 3 | 1.0 |
Receptors, Immunologic/*immunology | 2 | 1.0 |
*Skin Physiology | 2 | 5.0 |
*Gene Expression Regulation | 7 | 0.0 |
CD4-Positive T-Lymphocytes/drug effects/metabolism | 2 | 15.0 |
Membrane Glycoproteins/*physiology | 4 | 1.0 |
Chromosome Mapping | 11 | 0.0 |
Sequence Alignment | 5 | 0.0 |
T-Lymphocytes/*metabolism | 14 | 3.0 |
Antigens, CD30/metabolism | 2 | 10.0 |
Antigens, CD80/metabolism | 2 | 2.0 |
*Immunoconjugates | 5 | 1.0 |
Cell Adhesion Molecules/*analysis | 2 | 1.0 |
Immunologic Memory/*immunology | 3 | 9.0 |
Lymph Nodes/*immunology | 2 | 5.0 |
*Adjuvants, Immunologic | 2 | 6.0 |
Antigens, Differentiation/analysis | 5 | 1.0 |
Gene Expression | 10 | 0.0 |
Immunosuppressive Agents/therapeutic use | 3 | 1.0 |
Linkage (Genetics) | 3 | 0.0 |
Histocompatibility Antigens Class II/*physiology | 2 | 9.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics | 3 | 4.0 |
Structure-Activity Relationship | 2 | 0.0 |
Tacrolimus/pharmacology | 3 | 6.0 |
CD8-Positive T-Lymphocytes/cytology/immunology | 2 | 7.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Cell Transformation, Viral | 3 | 1.0 |
Simian Acquired Immunodeficiency Syndrome/*immunology | 2 | 11.0 |
Immunity, Natural | 3 | 1.0 |
Cytotoxicity, Immunologic/*drug effects | 2 | 2.0 |
Candida/immunology | 2 | 16.0 |
Epitopes | 5 | 0.0 |
Flow Cytometry/economics | 2 | 100.0 |
*Fluoresceins | 2 | 33.0 |
*Fluorescent Dyes | 2 | 6.0 |
Immunologic Deficiency Syndromes/diagnosis/*immunology | 2 | 100.0 |
*Succinimides | 2 | 33.0 |
T-Lymphocytes/cytology/*immunology/metabolism | 3 | 14.0 |
Alkaloids/*pharmacology | 3 | 5.0 |
Antigens, CD28/*physiology | 3 | 3.0 |
*Benzylisoquinolines | 3 | 27.0 |
Isoquinolines/pharmacology | 3 | 2.0 |
*Tetrahydroisoquinolines | 2 | 3.0 |
Adjuvants, Immunologic/pharmacology | 3 | 3.0 |
Cytokines/*pharmacology | 2 | 0.0 |
DNA/biosynthesis | 3 | 0.0 |
Interleukin-1/biosynthesis | 2 | 1.0 |
Chromosomes, Human, Pair 12 | 6 | 3.0 |
*Killer Cells, Natural | 3 | 13.0 |
Lectins/*genetics | 2 | 22.0 |
Receptors, Cell Surface/*genetics | 2 | 0.0 |
Injections, Intravenous | 2 | 0.0 |
Killer Cells, Natural/*immunology/metabolism | 2 | 5.0 |
Mice, Inbred Strains | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 2 | 3.0 |
Bone Marrow/immunology | 2 | 1.0 |
Hematopoietic Stem Cells/*immunology | 2 | 1.0 |
Spleen/immunology | 4 | 2.0 |
Antigens, CD56/immunology | 3 | 21.0 |
Major Histocompatibility Complex/*immunology | 2 | 5.0 |
Minor Histocompatibility Antigens/*immunology | 2 | 33.0 |
Lactones/*pharmacology | 2 | 6.0 |
Membrane Glycoproteins/*pharmacology | 2 | 2.0 |
Cell Separation | 15 | 1.0 |
Enterotoxins/pharmacology | 2 | 3.0 |
Lymphocyte Subsets | 7 | 3.0 |
Superantigens/pharmacology | 3 | 12.0 |
Thymidine/*metabolism | 2 | 11.0 |
Antibodies, Monoclonal/*immunology | 5 | 0.0 |
Antigens, CD28/*immunology | 3 | 2.0 |
HIV-1/immunology/*physiology | 2 | 3.0 |
CD4-Positive T-Lymphocytes/immunology/*physiology | 2 | 15.0 |
Cell Adhesion Molecules/*physiology | 3 | 2.0 |
Intercellular Adhesion Molecule-1/*physiology | 2 | 12.0 |
Killer Cells, Natural/immunology/*metabolism | 2 | 6.0 |
Receptors, IgG/immunology | 3 | 8.0 |
Antigens, CD/*biosynthesis/genetics | 2 | 3.0 |
Fluorescein-5-isothiocyanate/metabolism | 2 | 10.0 |
HIV-1/genetics/*immunology | 2 | 2.0 |
*Viral Load | 3 | 1.0 |
Antigens, CD/chemistry/*physiology | 2 | 14.0 |
Antigens, Differentiation, T-Lymphocyte/chemistry/*physiology | 2 | 33.0 |
Nitric Oxide/biosynthesis | 2 | 2.0 |
Receptors, Immunologic/*metabolism | 2 | 1.0 |
T-Lymphocyte Subsets/*cytology/*immunology | 2 | 33.0 |
Bronchoalveolar Lavage Fluid/cytology | 5 | 4.0 |
Interleukin-5/analysis | 2 | 15.0 |
Interleukins/analysis | 2 | 6.0 |
Bronchoalveolar Lavage Fluid/*immunology | 2 | 6.0 |
Antigens, CD44/biosynthesis | 2 | 6.0 |
CD4-Positive T-Lymphocytes/drug effects/*immunology/metabolism | 3 | 33.0 |
Skin/immunology/pathology | 2 | 4.0 |
Cytokines/genetics | 4 | 3.0 |
Promoter Regions (Genetics)/drug effects/immunology | 3 | 30.0 |
Transcription, Genetic/drug effects/immunology | 2 | 12.0 |
Cytotoxicity, Immunologic/immunology | 2 | 2.0 |
HLA Antigens/biosynthesis | 3 | 20.0 |
Histocompatibility Antigens Class II/biosynthesis | 2 | 4.0 |
*Antigens, Differentiation | 6 | 6.0 |
Cell Adhesion Molecules/*metabolism | 3 | 1.0 |
Antigens, CD/*biosynthesis/blood | 2 | 16.0 |
Immunologic Surveillance | 2 | 7.0 |
Histocompatibility Testing | 4 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 4 | 2.0 |
*Blood | 2 | 4.0 |
T-Lymphocyte Subsets/cytology/immunology | 2 | 11.0 |
Interleukin-2/*biosynthesis | 8 | 5.0 |
Immunoglobulins, Intravenous/*administration & dosage | 2 | 25.0 |
Allergens/*immunology | 2 | 2.0 |
Interferon Type II/immunology | 3 | 3.0 |
Receptors, Antigen, T-Cell, gamma-delta/*immunology | 8 | 16.0 |
Receptors, Cell Surface/immunology | 2 | 5.0 |
Immunoglobulin E/blood | 3 | 2.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 3 | 0.0 |
*Membrane Proteins | 2 | 0.0 |
Mutation | 6 | 0.0 |
Hybridomas | 3 | 2.0 |
Clonal Anergy | 3 | 8.0 |
Polymorphism, Genetic | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
CD8-Positive T-Lymphocytes/*metabolism | 2 | 5.0 |
Leukocytes, Mononuclear/*metabolism | 2 | 1.0 |
Decidua/*immunology | 5 | 27.0 |
Pregnancy Trimester, First | 4 | 1.0 |
Cell Line, Tumor | 7 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1 | 2 | 1.0 |
Protein-Tyrosine Kinase/chemistry/genetics/*metabolism | 2 | 8.0 |
src Homology Domains | 3 | 0.0 |
Antigens, CD2/physiology | 2 | 8.0 |
Antigens, CD28/physiology | 4 | 4.0 |
Receptors, Interleukin-2/*analysis | 5 | 7.0 |
Tumor Necrosis Factor-alpha/*analysis | 3 | 1.0 |
Interleukin-1/secretion | 2 | 4.0 |
Leukocytes, Mononuclear/*immunology | 6 | 3.0 |
Antigens, CD14/analysis | 2 | 1.0 |
Antigens, CD26/analysis | 2 | 33.0 |
Bronchoalveolar Lavage Fluid/immunology | 4 | 11.0 |
Cell Adhesion Molecules/analysis | 4 | 2.0 |
Receptors, IgG/analysis | 3 | 4.0 |
Th1 Cells/immunology | 3 | 1.0 |
Cyclic AMP/*physiology | 2 | 2.0 |
Interleukin-2/physiology | 3 | 3.0 |
Interleukin-4/physiology | 2 | 5.0 |
Membrane Glycoproteins/*analysis | 2 | 1.0 |
*Down-Regulation | 2 | 0.0 |
Protein Kinase C/*physiology | 2 | 2.0 |
T-Lymphocytes/*drug effects | 5 | 7.0 |
Cytokines/*analysis | 2 | 2.0 |
*T-Lymphocyte Subsets | 5 | 6.0 |
Eosinophils/*drug effects | 2 | 18.0 |
Interleukin-13/*pharmacology | 2 | 4.0 |
Interleukin-4/*pharmacology | 4 | 1.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 4 | 0.0 |
HLA Antigens/metabolism | 2 | 6.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Antigens, CD/physiology | 2 | 0.0 |
Membrane Glycoproteins/physiology | 3 | 1.0 |
Lymphocyte Activation/drug effects/*physiology | 2 | 11.0 |
Interleukin-4/*biosynthesis | 2 | 3.0 |
Isoantigens/immunology | 2 | 2.0 |
Tissue Donors | 2 | 0.0 |
Antibody Specificity | 3 | 0.0 |
Cell Adhesion Molecules/*immunology | 2 | 3.0 |
Cell Adhesion | 7 | 0.0 |
Lymphocyte Function-Associated Antigen-1/*physiology | 2 | 4.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Isoxazoles/*pharmacology | 2 | 22.0 |
Membrane Glycoproteins/*genetics | 4 | 0.0 |
RNA, Messenger | 2 | 0.0 |
Tyrosine/chemistry | 2 | 1.0 |
src-Family Kinases/metabolism | 2 | 1.0 |
Bronchial Provocation Tests | 2 | 2.0 |
Eosinophils/immunology | 3 | 5.0 |
T-Lymphocytes/drug effects/physiology | 2 | 13.0 |
Antigens, CD95/physiology | 2 | 2.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Antigens, CD4/metabolism | 3 | 0.0 |
Immunophenotyping/methods | 3 | 6.0 |
HIV Seropositivity/*immunology | 2 | 2.0 |
Interferon Alfa-2b/pharmacology | 2 | 22.0 |
Immune Tolerance/*drug effects | 2 | 11.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Sodium-Hydrogen Antiporter/metabolism | 2 | 33.0 |
Antibody Formation | 2 | 0.0 |
Antigens, Surface/immunology | 3 | 1.0 |
T-Lymphocytes/cytology/*immunology | 5 | 3.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Diabetes Mellitus, Type 1/*immunology | 5 | 7.0 |
*Lymphocyte Count | 2 | 4.0 |
Antigens, CD2 | 4 | 0.0 |
Antigens, CD3 | 6 | 1.0 |
Body Mass Index | 2 | 0.0 |
Antigens, CD/analysis/*metabolism | 3 | 20.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*metabolism | 3 | 37.0 |
Menstrual Cycle/*immunology | 2 | 20.0 |
HIV Infections/blood/*immunology | 2 | 3.0 |
Lupus Erythematosus, Systemic/*immunology | 3 | 2.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Interleukin-6/metabolism | 3 | 1.0 |
Lymphocyte Function-Associated Antigen-1/metabolism | 3 | 6.0 |
Antigens, CD8/genetics | 2 | 13.0 |
Receptors, Antigen, T-Cell/genetics | 2 | 2.0 |
Antigens, CD1/analysis | 2 | 2.0 |
Cell Line, Transformed | 2 | 0.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Superoxides/metabolism | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism | 3 | 4.0 |
Simplexvirus/immunology | 2 | 9.0 |
Immunocompromised Host | 2 | 2.0 |
Longitudinal Studies | 2 | 0.0 |
Receptors, IgE/*immunology | 2 | 12.0 |
CD4-Positive T-Lymphocytes/*drug effects/*immunology | 2 | 40.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Blotting, Northern | 5 | 0.0 |
Cross-Linking Reagents | 3 | 0.0 |
Isoantigens | 2 | 7.0 |
Cell Aggregation/drug effects/immunology | 2 | 33.0 |
Antigens, CD8/immunology | 4 | 5.0 |
Mitogens/*pharmacology | 4 | 3.0 |
Superantigens/*pharmacology | 2 | 7.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Antigens, CD3/physiology | 6 | 8.0 |
HLA-DR Antigens/*biosynthesis | 3 | 10.0 |
Mice, Inbred C3H | 2 | 0.0 |
Killer Cells, Lymphokine-Activated/*immunology | 3 | 4.0 |
Multigene Family | 5 | 0.0 |
Receptor-CD3 Complex, Antigen, T-Cell/*physiology | 3 | 13.0 |
Cell Compartmentation | 2 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 3 | 0.0 |
Second Messenger Systems | 2 | 2.0 |
Staphylococcus aureus/*immunology | 2 | 2.0 |
*Desensitization, Immunologic | 2 | 7.0 |
Interleukin-4/metabolism | 2 | 2.0 |
Oxidation-Reduction | 3 | 0.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
Consensus Sequence | 3 | 0.0 |
Antigens, CD3/*analysis | 5 | 16.0 |
Cell Adhesion/immunology | 6 | 3.0 |
Intercellular Adhesion Molecule-1/immunology | 2 | 4.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Antigens, CD/analysis/*physiology | 3 | 10.0 |
Antigens, CD27/analysis | 2 | 11.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*physiology | 2 | 22.0 |
*Homeodomain Proteins | 2 | 0.0 |
Stem Cells/cytology/immunology | 2 | 11.0 |
Membrane Glycoproteins/*metabolism | 3 | 0.0 |
Synovial Fluid/*immunology | 3 | 5.0 |
Synovitis/immunology | 2 | 25.0 |
Interleukin-7/*pharmacology | 2 | 4.0 |
Phytohemagglutinins | 5 | 5.0 |
B-Lymphocytes/cytology | 2 | 2.0 |
Bromodeoxyuridine/metabolism | 2 | 2.0 |
Blood Proteins/biosynthesis | 2 | 9.0 |
CD8-Positive T-Lymphocytes/drug effects/metabolism | 2 | 28.0 |
Receptors, Antigen, T-Cell, alpha-beta/metabolism | 2 | 6.0 |
Macrophage Activation/drug effects | 2 | 3.0 |
Receptors, Antigen, T-Cell, alpha-beta/*immunology | 3 | 5.0 |
Phagocytosis | 2 | 0.0 |
Cell Cycle/drug effects | 4 | 0.0 |
Phytohemagglutinins/*pharmacology | 3 | 8.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 4 | 1.0 |
*Immune Tolerance | 2 | 1.0 |
Monocytes/drug effects/immunology | 2 | 5.0 |
Graft Rejection/immunology/*pathology | 2 | 28.0 |
Antigens, CD95/biosynthesis | 2 | 6.0 |
DNA/metabolism | 4 | 0.0 |
Eosinophils/*pathology | 2 | 14.0 |
Bone Marrow Cells | 2 | 0.0 |
Macrophages/*immunology | 2 | 0.0 |
Mice, Inbred CBA | 3 | 0.0 |
Receptors, Immunologic/*physiology | 2 | 1.0 |
Cell Death/immunology | 2 | 6.0 |
Epithelial Cells | 2 | 0.0 |
Synovial Membrane/*immunology | 2 | 5.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
*Chromosomes, Human, Pair 12 | 5 | 1.0 |
Spleen/cytology | 3 | 1.0 |
Antigen-Presenting Cells/*immunology | 2 | 1.0 |
Antigens, CD28/immunology | 5 | 3.0 |
Tumor Necrosis Factor-alpha/*immunology | 3 | 2.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Gestational Age | 2 | 0.0 |
Hematopoietic Stem Cells/immunology | 2 | 2.0 |
HLA-DR Antigens/*immunology | 2 | 1.0 |
Receptor Aggregation | 4 | 4.0 |
Carcinoma, Renal Cell/*immunology | 2 | 11.0 |
Kidney Neoplasms/*immunology | 2 | 7.0 |
Lymphocytes, Tumor-Infiltrating/*immunology | 4 | 5.0 |
Interleukins/pharmacology | 4 | 5.0 |
Immunosuppressive Agents/*pharmacology/therapeutic use | 2 | 22.0 |
Peptides/*pharmacology/therapeutic use | 2 | 50.0 |
Microscopy, Electron | 2 | 0.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 2 | 0.0 |
Antigens, CD45/*metabolism | 4 | 12.0 |
Antigens, CD95/*metabolism | 3 | 2.0 |
Lupus Erythematosus, Systemic/blood/*immunology | 2 | 5.0 |
Antigens, CD/*genetics | 7 | 2.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
*Receptors, Immunologic | 2 | 1.0 |
Lymphocytes/*physiology | 3 | 3.0 |
Antigens, CD/*biosynthesis/drug effects | 2 | 50.0 |
Antigens, Differentiation, T-Lymphocyte/*biosynthesis/drug effects | 2 | 100.0 |
Calcium/*metabolism | 5 | 0.0 |
Carcinogens/pharmacology | 4 | 4.0 |
Genes, Structural | 2 | 0.0 |
Thymus Gland/cytology/*immunology | 2 | 6.0 |
Mice, Inbred DBA | 2 | 0.0 |
Antigens, CD/biosynthesis/drug effects | 4 | 44.0 |
Histocompatibility Antigens Class I/*immunology | 2 | 1.0 |
Leukocytes, Mononuclear/cytology/*immunology | 2 | 22.0 |
Killer Cells, Natural/*drug effects | 2 | 6.0 |
Immunity, Cellular/drug effects | 2 | 3.0 |
T-Lymphocytes, Cytotoxic/drug effects/*immunology | 2 | 9.0 |
Palate/immunology | 2 | 100.0 |
Tonsil/*immunology | 2 | 11.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
Interleukin-2/*metabolism | 2 | 4.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Trophoblasts/*immunology | 2 | 6.0 |
Signal Transduction/physiology | 2 | 0.0 |
Interleukin-10/*biosynthesis | 3 | 4.0 |
Arthritis, Rheumatoid/*pathology | 2 | 10.0 |
Synovial Fluid/*cytology | 2 | 12.0 |
T-Lymphocytes/cytology/*physiology | 2 | 12.0 |
Lymphocytes/metabolism | 4 | 1.0 |
CD4-Positive T-Lymphocytes/*cytology | 2 | 4.0 |
Inflammation/metabolism | 2 | 2.0 |
Lung/immunology | 2 | 6.0 |
Survival Rate | 3 | 0.0 |
Intensive Care Units | 2 | 3.0 |
Phagocytosis/drug effects | 2 | 2.0 |
Interleukins/*pharmacology | 5 | 6.0 |
T-Lymphocyte Subsets/*drug effects/immunology | 2 | 9.0 |
*Immunotherapy, Active | 2 | 8.0 |
T-Lymphocyte Subsets/*cytology/immunology | 2 | 22.0 |
Receptors, Antigen, T-Cell, gamma-delta/analysis | 3 | 8.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Enterotoxins/*pharmacology | 2 | 3.0 |
Interleukin-8/metabolism | 2 | 1.0 |
In Situ Hybridization/methods | 2 | 1.0 |
Fluorescence | 2 | 0.0 |
Light | 2 | 0.0 |
Scattering, Radiation | 2 | 1.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors | 2 | 3.0 |
T-Lymphocytes/drug effects/immunology/metabolism | 2 | 11.0 |
Integrins/metabolism | 3 | 1.0 |
Immunoglobulin M/blood | 2 | 1.0 |
CD8-Positive T-Lymphocytes/immunology/*physiology | 2 | 50.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 0.0 |
HIV Seropositivity/immunology | 3 | 3.0 |
Leukocytes, Mononuclear/*drug effects | 2 | 11.0 |
G1 Phase/drug effects | 2 | 1.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Thymus Gland/*cytology/immunology | 2 | 10.0 |
Drug Therapy, Combination | 2 | 0.0 |
Multiple Sclerosis/drug therapy/*immunology | 2 | 28.0 |
Tumor Cells, Cultured/immunology | 2 | 2.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
Antigens, CD5 | 3 | 1.0 |
Antigens, CD/*biosynthesis/*genetics | 2 | 20.0 |
Antigens, Differentiation, T-Lymphocyte/*biosynthesis/*genetics | 2 | 66.0 |
Base Composition | 2 | 0.0 |
*Immediate-Early Proteins | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Interleukin-5/biosynthesis | 2 | 5.0 |
T-Lymphocytes/immunology/*physiology | 2 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis/drug effects | 3 | 100.0 |
Genistein | 3 | 4.0 |
Isoflavones/pharmacology | 2 | 3.0 |
Phosphotyrosine | 2 | 0.0 |
Receptors, Interleukin-2/physiology | 4 | 8.0 |
Thymus Gland/cytology | 2 | 2.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Antigens, CD4/*biosynthesis | 2 | 4.0 |
Transcription, Genetic/drug effects/*immunology | 2 | 22.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Tumor Necrosis Factor-alpha/immunology | 2 | 1.0 |
Blood Cells/immunology | 3 | 9.0 |
Buserelin/*pharmacology | 2 | 33.0 |
Receptors, Interleukin-2/drug effects/immunology | 2 | 100.0 |
Antigens, Surface/*analysis | 2 | 1.0 |
Antigens, CD40 | 2 | 3.0 |
B-Lymphocytes/*drug effects/immunology | 4 | 13.0 |
T-Lymphocytes/*chemistry | 2 | 9.0 |
Antigens, CD29 | 2 | 3.0 |
Cell Communication/immunology | 3 | 3.0 |
Antigens, CD28/biosynthesis | 2 | 6.0 |
Interleukin-2/*immunology | 2 | 3.0 |
Interferon Type I, Recombinant/*pharmacology | 3 | 6.0 |
Killer Cells, Natural/*physiology | 3 | 6.0 |
Tumor Necrosis Factor-alpha/*secretion | 2 | 2.0 |
Receptors, CCR5/analysis | 2 | 4.0 |
Th2 Cells/immunology | 3 | 1.0 |
Phorbol Esters/pharmacology | 2 | 1.0 |
Synovial Fluid/immunology | 2 | 5.0 |
Synovial Membrane/immunology | 2 | 6.0 |
Antigens, CD56 | 3 | 4.0 |
Antigens, CD57 | 2 | 3.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Cell Adhesion Molecules/blood | 2 | 6.0 |
Cyclosporine/therapeutic use | 2 | 2.0 |
Lymphocyte Function-Associated Antigen-1/*metabolism | 2 | 7.0 |
Receptor-CD3 Complex, Antigen, T-Cell/immunology | 2 | 8.0 |
Antigens, Differentiation, T-Lymphocyte/*genetics | 6 | 11.0 |
Antigens, Surface/biosynthesis | 2 | 3.0 |
Cytoplasm/immunology | 4 | 4.0 |
Interleukin-12 | 3 | 17.0 |
Receptors, Immunologic/metabolism | 3 | 1.0 |
T-Lymphocytes/physiology | 2 | 1.0 |
T-Lymphocyte Subsets/immunology/*physiology | 2 | 15.0 |
Interleukin-2/*physiology | 2 | 2.0 |
Signal Transduction/genetics/immunology | 2 | 2.0 |
Hybrid Cells | 2 | 0.0 |
Risk Assessment | 2 | 0.0 |
Antigens, CD27 | 2 | 4.0 |
Antigens, CD45/physiology | 2 | 13.0 |
Quinones/pharmacology | 2 | 1.0 |
Receptors, Antigen, T-Cell, gamma-delta/*analysis | 3 | 7.0 |
Interferon Type II/*biosynthesis | 2 | 1.0 |
Cell Adhesion Molecules/biosynthesis | 2 | 2.0 |
Antigens, CD28 | 6 | 4.0 |
T-Lymphocytes/cytology/*drug effects/metabolism | 2 | 25.0 |
Calcium/immunology | 2 | 20.0 |
Interleukin-1/*biosynthesis | 2 | 1.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Antigens, CD/*analysis/physiology | 2 | 16.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/physiology | 2 | 28.0 |
Antigens, Differentiation, B-Lymphocyte/metabolism | 4 | 6.0 |
Interferon-alpha/*therapeutic use | 2 | 3.0 |
Leukocytes, Mononuclear/drug effects/immunology | 3 | 6.0 |
Antigens, CD4/genetics | 2 | 3.0 |
Antigens, CD8/biosynthesis | 2 | 5.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
L-Selectin/metabolism | 3 | 9.0 |
Neutrophils/drug effects/metabolism | 2 | 6.0 |
Receptors, IgG | 2 | 1.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
B-Lymphocytes/immunology/metabolism | 2 | 3.0 |
Interleukin-4/secretion | 2 | 4.0 |
Intercellular Adhesion Molecule-1 | 2 | 0.0 |
T-Lymphocyte Subsets/immunology/metabolism | 2 | 4.0 |
*Blood Proteins | 2 | 2.0 |
*Peptides | 2 | 3.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Antigens, CD/immunology/metabolism | 3 | 5.0 |
Antigens, CD/analysis/*immunology | 2 | 5.0 |
Receptors, Interleukin-2/biosynthesis/*immunology | 2 | 50.0 |
Depression, Chemical | 2 | 1.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 2 | 1.0 |
Gene Expression Profiling | 2 | 0.0 |
Cytokines/immunology/metabolism | 2 | 9.0 |
Triazines/adverse effects | 2 | 66.0 |
Calcium Signaling | 2 | 2.0 |
Syndrome | 2 | 0.0 |
Spondylitis, Ankylosing/*immunology | 2 | 13.0 |
Antigens, CD3/pharmacology | 2 | 12.0 |
Receptors, IgG/biosynthesis | 2 | 7.0 |
CD4-Positive T-Lymphocytes/*immunology/*metabolism | 2 | 15.0 |
